AbbVie and Genmab's Epkinly shows positive combo results, moving toward label expansion in DLBCL

AbbVie and Genmab reported that their bispecific antibody Epkinly achieved a successful outcome when tested together with a commonly used cancer therapy. The data indicate that the combination was effective in patients with diffuse large B-cell lymphoma.

The favorable result brings the drug one step closer to gaining an expanded indication for this aggressive lymphoma type. If regulatory agencies accept the findings, Epkinly could be added to treatment options for a broader patient population.

The companies plan to submit the data to health authorities and may initiate further studies to confirm the benefit. Stakeholders will watch for formal label update announcements in the coming months.